Gender and tumor location as predictors for efficacy: Influence on endpoints in first-line treatment with FOLFIRI in combination with cetuximab or bevacizumab in the AIO KRK 0306 (FIRE3) trial.
Volker Heinemann
Consultant or Advisory Role - Merck Serono; Roche
Honoraria - Merck KGaA; Roche
Research Funding - Merck Serono; Roche
Other Remuneration - Merck
Dominik Paul Modest
Consultant or Advisory Role - Merck; Roche
Honoraria - Merck; Roche
Other Remuneration - Merck; Roche
Ludwig Fischer von Weikersthal
Other Remuneration - Roche
Thomas Decker
No relevant relationships to disclose
Alexander Kiani
No relevant relationships to disclose
Ursula Vehling-Kaiser
No relevant relationships to disclose
Salah-Eddin Al-Batran
No relevant relationships to disclose
Tobias Heintges
No relevant relationships to disclose
Christian A. Lerchenmuller
No relevant relationships to disclose
Christoph Kahl
No relevant relationships to disclose
Gernot Seipelt
No relevant relationships to disclose
Frank Kullmann
Honoraria - Roche
Martina Stauch
No relevant relationships to disclose
Werner Scheithauer
Consultant or Advisory Role - Merck Serono; Roche
Honoraria - Merck Serono; Roche
Swantje Held
No relevant relationships to disclose
Clemens Albrecht Giessen
Other Remuneration - Roche
Andreas Jung
Consultant or Advisory Role - Merck Serono
Honoraria - Merck Serono
Thomas Kirchner
Consultant or Advisory Role - Amgen; Novartis; Pfizer; Roche
Honoraria - Amgen; AstraZeneca; Merck Serono; Roche
Research Funding - Amgen; Merck Serono
Sebastian Stintzing
Consultant or Advisory Role - Bristol-Myers Squibb; Merck KGaA; Roche/Genentech
Honoraria - Amgen; Merck KGaA; Roche/Genentech; Sanofi
Other Remuneration - Merck Serono; Roche